JP2004536879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536879A5 JP2004536879A5 JP2003517002A JP2003517002A JP2004536879A5 JP 2004536879 A5 JP2004536879 A5 JP 2004536879A5 JP 2003517002 A JP2003517002 A JP 2003517002A JP 2003517002 A JP2003517002 A JP 2003517002A JP 2004536879 A5 JP2004536879 A5 JP 2004536879A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 108700012411 TNFSF10 Proteins 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229940080856 gleevec Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940084651 iressa Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- -1 vinca alkaloids Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000464A ITRM20010464A1 (it) | 2001-07-31 | 2001-07-31 | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
| PCT/IT2002/000474 WO2003011808A1 (en) | 2001-07-31 | 2002-07-18 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536879A JP2004536879A (ja) | 2004-12-09 |
| JP2004536879A5 true JP2004536879A5 (enExample) | 2006-01-05 |
| JP4463550B2 JP4463550B2 (ja) | 2010-05-19 |
Family
ID=11455702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003517002A Expired - Fee Related JP4463550B2 (ja) | 2001-07-31 | 2002-07-18 | 抗血管新生、抗腫瘍性およびアポトーシス促進性の活性を有するレチノイド誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8101793B2 (enExample) |
| EP (1) | EP1412317B1 (enExample) |
| JP (1) | JP4463550B2 (enExample) |
| KR (1) | KR100888466B1 (enExample) |
| CN (1) | CN1279014C (enExample) |
| AT (1) | ATE492526T1 (enExample) |
| AU (1) | AU2002326144B2 (enExample) |
| BR (1) | BR0211521A (enExample) |
| CA (1) | CA2454532C (enExample) |
| CY (1) | CY1114535T1 (enExample) |
| DE (1) | DE60238683D1 (enExample) |
| DK (1) | DK1412317T3 (enExample) |
| ES (1) | ES2358097T3 (enExample) |
| HU (1) | HU229308B1 (enExample) |
| IT (1) | ITRM20010464A1 (enExample) |
| MX (1) | MXPA04000877A (enExample) |
| PL (1) | PL207530B1 (enExample) |
| PT (1) | PT1412317E (enExample) |
| WO (1) | WO2003011808A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| ITRM20010464A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
| EP1456165A1 (en) * | 2001-11-30 | 2004-09-15 | The Burnham Institute | Induction of apoptosis in cancer cells |
| CN1610696A (zh) * | 2001-12-20 | 2005-04-27 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
| EP1856063B1 (en) | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
| AU2006233810B2 (en) | 2005-04-08 | 2011-02-17 | Galderma Research & Development | New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid |
| FR2884248B1 (fr) * | 2005-04-08 | 2007-05-18 | Galderma Res & Dev | Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique |
| ITRM20050248A1 (it) * | 2005-05-20 | 2006-11-21 | Sigma Tau Ind Farmaceuti | Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee. |
| ES2356129T3 (es) * | 2005-06-28 | 2011-04-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Derivados de ácido bifenil y naftil-fenil hidroxámico. |
| WO2007037188A1 (ja) * | 2005-09-27 | 2007-04-05 | Sapporo Medical University | 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬 |
| WO2007071605A1 (en) * | 2005-12-19 | 2007-06-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | The use of st1898 for the treatment of restenosis |
| JP5054006B2 (ja) * | 2006-06-23 | 2012-10-24 | ロート製薬株式会社 | ヒアルロン酸産生促進能を有する組成物 |
| WO2008077772A2 (en) * | 2006-12-22 | 2008-07-03 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Combination of a retinoid and a platinum anticancer agent |
| WO2010000784A1 (en) * | 2008-07-03 | 2010-01-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treatment of restenosis |
| TW201031402A (en) * | 2008-12-24 | 2010-09-01 | Sigma Tau Ind Farmaceuti | New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties |
| US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010106135A1 (en) | 2009-03-20 | 2010-09-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combined use for the treatment of ovarian carcinoma |
| US9096544B2 (en) | 2009-12-23 | 2015-08-04 | Wayne State University | Therapeutic compounds |
| PT2758371T (pt) * | 2011-09-19 | 2016-07-13 | Sigma Tau Ind Farmaceuti | Novos tio derivados que contêm lactamas como potentes inibidores de hdac e suas utilizações enquanto medicamentos |
| JP5757602B2 (ja) * | 2012-05-11 | 2015-07-29 | 国立大学法人金沢大学 | 不斉選択性の切り替えが可能なクロマトグラフィー用充填剤 |
| CN104496839B (zh) * | 2014-12-03 | 2016-04-20 | 广东东阳光药业有限公司 | 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途 |
| US11707442B2 (en) | 2015-09-25 | 2023-07-25 | The General Hospital Corporation | Antibacterial and antifungal compounds |
| CA3011538A1 (en) | 2016-01-18 | 2017-07-27 | Arisan Therapeutics | Adamantane derivatives for the treatment of filovirus infection |
| EP3301085A1 (en) | 2016-09-29 | 2018-04-04 | Biogem S.Ca.R.L. | Retinoid derivatives with antitumor activity |
| CN110799182B (zh) * | 2017-04-27 | 2024-02-20 | 范德比尔特大学 | 用γ-酮醛清除剂治疗动脉粥样硬化的方法 |
| WO2018213609A1 (en) | 2017-05-17 | 2018-11-22 | Ausubel Frederick M | Antibiotic compounds |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| IT201900003343A1 (it) * | 2019-03-07 | 2020-09-07 | Special Product’S Line S P A | Derivati fenolici per uso come antimicrobici, antibatterici, battericidi |
| CN111956806B (zh) * | 2020-09-03 | 2023-04-07 | 四川大学 | 一种药物载体、胶束、药剂及其制备方法和应用 |
| IT202000029882A1 (it) * | 2020-12-04 | 2022-06-04 | Special Product’S Line S P A | Derivati fenolici per uso come antimicrobici, antibatterici, battericidi |
| IT202000029906A1 (it) * | 2020-12-04 | 2022-06-04 | Special Product’S Line S P A | Derivati fenolici per uso come antimicrobici, antibatterici, battericidi. |
| WO2022229017A1 (en) | 2021-04-27 | 2022-11-03 | Biogem S.C.A R.L. | Adamantyl retinoid derivative with anticancer activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676052B1 (fr) * | 1991-05-02 | 1994-04-29 | Cird Galderma | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique. |
| CZ3499A3 (cs) * | 1996-07-08 | 1999-11-17 | Galderma Research & Development, S. N. C. | Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující |
| ITRM20010464A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
| EP1456165A1 (en) * | 2001-11-30 | 2004-09-15 | The Burnham Institute | Induction of apoptosis in cancer cells |
-
2001
- 2001-07-31 IT IT2001RM000464A patent/ITRM20010464A1/it unknown
-
2002
- 2002-07-18 AT AT02760553T patent/ATE492526T1/de active
- 2002-07-18 DE DE60238683T patent/DE60238683D1/de not_active Expired - Lifetime
- 2002-07-18 WO PCT/IT2002/000474 patent/WO2003011808A1/en not_active Ceased
- 2002-07-18 AU AU2002326144A patent/AU2002326144B2/en not_active Ceased
- 2002-07-18 JP JP2003517002A patent/JP4463550B2/ja not_active Expired - Fee Related
- 2002-07-18 ES ES02760553T patent/ES2358097T3/es not_active Expired - Lifetime
- 2002-07-18 PT PT02760553T patent/PT1412317E/pt unknown
- 2002-07-18 DK DK02760553.4T patent/DK1412317T3/da active
- 2002-07-18 US US10/485,530 patent/US8101793B2/en not_active Expired - Fee Related
- 2002-07-18 PL PL368412A patent/PL207530B1/pl not_active IP Right Cessation
- 2002-07-18 KR KR1020047001546A patent/KR100888466B1/ko not_active Expired - Fee Related
- 2002-07-18 MX MXPA04000877A patent/MXPA04000877A/es active IP Right Grant
- 2002-07-18 HU HU0401604A patent/HU229308B1/hu not_active IP Right Cessation
- 2002-07-18 CA CA2454532A patent/CA2454532C/en not_active Expired - Fee Related
- 2002-07-18 CN CNB028150082A patent/CN1279014C/zh not_active Expired - Fee Related
- 2002-07-18 EP EP02760553A patent/EP1412317B1/en not_active Expired - Lifetime
- 2002-07-18 BR BR0211521-2A patent/BR0211521A/pt not_active IP Right Cessation
-
2007
- 2007-06-20 US US11/765,737 patent/US7449495B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 CY CY20111100294T patent/CY1114535T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536879A5 (enExample) | ||
| CA2454532A1 (en) | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | |
| EP1104297B1 (en) | Compositions for the treatment of chronic lymphocytic leukemia | |
| JP6005855B2 (ja) | 血管破壊薬および低酸素を標的とする薬剤を含む併用療法 | |
| JP2006523216A5 (enExample) | ||
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| JP2006503850A5 (enExample) | ||
| JP2004529114A5 (enExample) | ||
| JP2003519228A5 (enExample) | ||
| JP2006515004A5 (enExample) | ||
| CN1283248C (zh) | 包含埃坡霉素的组合及其药学应用 | |
| AU2008236994A1 (en) | Method of treating melanoma | |
| JP2005527575A5 (enExample) | ||
| CN1750825A (zh) | 黄酮乙酸类似物以及其使用方法 | |
| JP2009541473A (ja) | 治療剤におけるイミダゾ［１，２−ａ］ピリジン−２−カルボキサミド誘導体の使用 | |
| RU2016110546A (ru) | Комбинированная лекарственная терапия | |
| CN1299348A (zh) | 用于治疗疾病的sPLA2抑制剂化合物 | |
| JP2010500971A5 (enExample) | ||
| JP2004528311A5 (enExample) | ||
| JP2007514732A5 (enExample) | ||
| JP2003535874A5 (enExample) | ||
| JP2019196361A (ja) | 置換フェニル−（１，３−ジヒドロ−イソインドール−２−イル）−メタノンを含んでなる医薬処方物 | |
| JPWO2023107606A5 (enExample) | ||
| CN1655822A (zh) | 含有acat抑制剂和胰岛素抵抗性改善剂的药用组合物 |